ReviewCurrent drug delivery2025

Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer.

Eknath Kole et al.PubMed ↗Publisher ↗

No numbers read from the abstract.